These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 31208827)

  • 21. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
    Amiot A; Serrero M; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Vuitton L; Viennot S; Bouguen G; Abitbol V; Fumery M; Gagniere C; Bouhnik Y;
    Aliment Pharmacol Ther; 2019 Jul; 50(1):40-53. PubMed ID: 31165509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
    Macaluso FS; Fries W; Renna S; Viola A; Muscianisi M; Cappello M; Guida L; Siringo S; Camilleri S; Garufi S; Privitera AC; Belluardo N; Giangreco E; Bertolami C; Vassallo R; Rizzuto G; Orlando R; Ventimiglia M; Orlando A;
    United European Gastroenterol J; 2020 Nov; 8(9):1045-1055. PubMed ID: 32772830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.
    Molander P; af Björkesten CG; Mustonen H; Haapamäki J; Vauhkonen M; Kolho KL; Färkkilä M; Sipponen T
    Inflamm Bowel Dis; 2012 Nov; 18(11):2011-7. PubMed ID: 22223566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.
    Dragoni G; Bagnoli S; Le Grazie M; Campani C; Rogai F; Manetti N; Bensi C; Macrì G; Galli A; Milla M
    J Dig Dis; 2019 May; 20(5):235-242. PubMed ID: 30927309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
    Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
    BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study.
    Kim K; Park JJ; Yoon H; Lee J; Kim KO; Kim ES; Kim SY; Boo SJ; Jung Y; Yoo JH; Hwang SW; Park SH; Yang SK; Ye BD;
    Aliment Pharmacol Ther; 2024 Jun; 59(12):1539-1550. PubMed ID: 38616380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
    Kopylov U; Ron Y; Avni-Biron I; Koslowsky B; Waterman M; Daher S; Ungar B; Yanai H; Maharshak N; Ben-Bassat O; Lichtenstein L; Bar-Gil Shitrit A; Israeli E; Schwartz D; Zittan E; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
    Inflamm Bowel Dis; 2017 Mar; 23(3):404-408. PubMed ID: 28178003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I
    J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.
    Engel T; Ungar B; Yung DE; Ben-Horin S; Eliakim R; Kopylov U
    J Crohns Colitis; 2018 Jan; 12(2):245-257. PubMed ID: 29077833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers.
    Tursi A; Mocci G; Faggiani R; Allegretta L; Valle ND; Forti G; Franceschi M; Ferronato A; Gallina S; Larussa T; Luzza F; Lorenzetti R; Penna A; Rodino S; Sebkova L; Lauria A; Piergallini S; Pranzo G; Ricciardelli C; Zampaletta C; Elisei W; Picchio M
    Ann Gastroenterol; 2019; 32(4):392-399. PubMed ID: 31263362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
    Ledder O; Assa A; Levine A; Escher JC; de Ridder L; Ruemmele F; Shah N; Shaoul R; Wolters VM; Rodrigues A; Uhlig HH; Posovszky C; Kolho KL; Jakobsen C; Cohen S; Shouval DS; de Meij T; Martin-de-Carpi J; Richmond L; Bronsky J; Friedman M; Turner D
    J Crohns Colitis; 2017 Oct; 11(10):1230-1237. PubMed ID: 28605483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
    Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
    Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T
    Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939
    [No Abstract]   [Full Text] [Related]  

  • 36. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
    Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
    Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination biologic therapy in pediatric inflammatory bowel disease: Safety and efficacy over a minimum 12-month follow-up period.
    Wlazlo M; Meglicka M; Wiernicka A; Osiecki M; Matuszczyk M; Kierkus J
    J Pediatr Gastroenterol Nutr; 2024 Jul; 79(1):54-61. PubMed ID: 38477410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis.
    Noman M; Ferrante M; Bisschops R; De Hertogh G; Van den Broeck K; Rans K; Rutgeerts P; Vermeire S; Van Assche G
    J Crohns Colitis; 2017 Sep; 11(9):1085-1089. PubMed ID: 28369329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
    Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
    J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.